Piper Sandler restated their overweight rating on shares of Korro Bio (NASDAQ:KRRO – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Piper Sandler currently has a $180.00 target price on the stock. A number of other research analysts have also recently issued reports on the company. Royal Bank of Canada […]
HC Wainwright restated their buy rating on shares of Korro Bio (NASDAQ:KRRO – Free Report) in a report published on Friday, Benzinga reports. The brokerage currently has a $100.00 price objective on the stock. A number of other brokerages also recently issued reports on KRRO. Royal Bank of Canada assumed coverage on Korro Bio in […]
Korro Bio (NASDAQ:KRRO – Get Free Report) is one of 977 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Korro Bio to similar companies based on the strength of its institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Profitability This table compares Korro […]
Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) Director David L. Lucchino sold 1,156 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $37.69, for a total transaction of $43,569.64. Following the transaction, the director now owns 22,150 shares of the company’s stock, […]
Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) Director David L. Lucchino sold 1,156 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $37.69, for a total transaction of $43,569.64. Following the transaction, the director now directly owns 22,150 shares of […]